Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-25 @ 3:46 AM
NCT ID:
NCT01030302
Eligibility Criteria:
Inclusion Criteria:
* Patients with multiple myeloma
* Patients who were treated with bortezomib monotherapy or bortezomib combination therapy
* Patients who relapsed after \>= six months interval since last dose of bortezomib
* Patients who had a treatment response of higher than partial remission (PR) to the previous bortezomib therapy
* Patients who were fully aware of the objectives and essential procedures of the current trial and then submitted a written informed consent declaring that they will voluntarily participate in the current trial
Exclusion Criteria:
* The current presence of or a past history of hypersensitivity to bortezomib or its constituents
* Severe hepatic dysfunction (AST or ALT at first use\>= x 5 upper normal)
* Pregnant women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01030302
Study Brief:
Protocol Section:
NCT01030302